Novartis (NVS) unit Novartis Pharmaceuticals Canada said Friday that negotiations with the pan-Canadian Pharmaceutical Alliance for Pluvicto, a treatment for patients with a certain type of prostate cancer, have closed without an agreement.
"This outcome is a significant setback for people living with [metastatic castration-resistant prostate cancer] whose cancer is progressing despite standard therapies," Novartis Canada said.
Price: 103.19, Change: -0.22, Percent Change: -0.21
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments